Fri, Nov 27, 2020
The 52 Week Low is $223.25 set on Mon, Nov 9, 2020.
The 52 Week High is $363.92 set on Wed, Nov 4, 2020.
The All-Time High is $442.29 set on Fri, Mar 20, 2015.
Earnings Per Share
Price To Earnings Ratio
Dividend Payment Date
Biogen trades on the NASDAQ. BIIB's market cap is 37.2 Billion.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.